Evidence map›Paper›PMID 21720747›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2012

Impact of marital status and race on outcomes of patients enrolled in Radiation Therapy Oncology Group prostate cancer trials.

Kevin Lee Du, Kyounghwa Bae, Benjamin Movsas, Yan Yan, Charlene Bryan, Deborah Watkins Bruner

3 registry-linked trialsAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00002602 phase1 / phase2completednot on this map

A phase i/ii dose escalation study using three dimensional conformal radiation therapy for adenocarcinoma of the prostate

TypeinterventionalSponsorRadiation Therapy Oncology GroupRan1994 to 2013Enrolled1,084ConditionsProstate CancerArms3D-CRT
NCT00767286 phase3completednot on this map

A phase iii trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate

TypeinterventionalSponsorRadiation Therapy Oncology GroupConditionsProstate CancerArmsflutamide, goserelin acetate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
NCT00769548 phase3completednot on this map

A phase iii trial comparing whole pelvic irradiation followed by a conedown boost to boost irradiation only and comparing neoadjuvant to adjuvant total androgen suppression (tas)

TypeinterventionalSponsorRadiation Therapy Oncology GroupRan1995 to 2016Enrolled1,322ConditionsProstate CancerArmsflutamide, goserelin acetate, low-LET photon therapy
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. African-American survivors of prostate cancer: a meta-synthesis of qualitative studies.Journal of cancer survivorship : research and practice · 2021
    Pooled it
  2. Trial
  3. Trial
  4. Voices of Black men: reflecting on prostate cancer survivorship care plans.Journal of cancer survivorship : research and practice · 2026
    Article
  5. Article
  6. Impact of Primary Tumor Resection on Survival of Patients with Metastatic Gallbladder Carcinoma: A Population-Based, Propensity‑Matched Study.Medical science monitor : international medical journal of experimental and clinical research · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Kevin Lee DuUniversity of Pennsylvania, Philadelphia, PA, USA. du@uphs.upenn.edu
Kyounghwa Bae
Benjamin Movsas
Yan Yan
Charlene Bryan
Deborah Watkins Bruner
RTOG Foundation · USUniversity of Pennsylvania · USHenry Ford Health System · USUniversity of Pennsylvania Health System · US

Funding

RTOG Foreign AccrualU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI CURRAN, WALTER J. · 1985 to 2013
$150.3M
NCI NIH HHS U10 CA021661
6 · The paper itself

Abstract

introductionPrevious studies by our group and others have demonstrated the importance of sociodemographic factors in cancer-related outcomes. The identification of these factors has led to novel approaches to the care of the high-risk cancer patient, specifically in the adoption of clinical interventions that convey similar benefits as favorable sociodemographic characteristics. This study examined the importance of marital status and race as prognostic indicators in men with prostate cancer.

methodsThis report is a meta-analysis of 3,570 patients with prostate cancer treated in three prospective RTOG clinical trials. The Kaplan-Meier method was used to estimate the survival rate and the cumulative incidence method was used to analyze biochemical failure rate. Hazard ratios were calculated for all covariates using either the Cox or Fine and Gray's proportional hazards model or logistic regression model with associated 95% confidence intervals and p values.

resultsHazard ratio (HR) for overall survival (OS) for single status compared to married status was 1.36 (95% CI, 1.2 to 1.53). OS HR for non-White compared to White patients was 1.05 (CI 0.92 to 1.21). In contrast, the disease-free survival (DFS) HR and biochemical failure (BF) HR were both not significantly different neither between single and married patients nor between White patients and non-White patients. Median time to death for married men was 5.68 years and for single men was 4.73 years. Median time for DFS for married men was 7.25 years and for single men was 6.56 years. Median time for BF for married men was 7.81 years and for single men was 7.05 years.

conclusionsRace was not associated with statistically significant differences in this analysis. Congruent with our previous work in other cancer sites, marital status predicted improved prostate cancer outcomes including overall survival. IMPLICATIONS FOR CANCER SURVIVORS: Prostate cancer is the most common visceral cancer in men in the USA. The stratification of prostate cancer risk is currently modeled solely on pathologic prognostic factors including PSA and Gleason Score. Independent of these pathologic prognostic factors, our paper describes the central sociodemographic factor of being single as a negative prognostic indicator. Single men are at high risk of poorer outcomes after prostate cancer treatment. Intriguingly, in our group of patients, race was not a significant prognostic factor. The findings in this paper add to the body of work that describes important sociodemographic prognostic factors that are currently underappreciated in patients with cancer. Future steps will include the validation of these findings in prospective studies, and the incorporation of clinical strategies that identify and compensate for sociodemographic factors that predict for poorer cancer outcomes.

Indexed as

AdultAgedAged, 80 and overClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsMaleMarital StatusMiddle AgedPrognosisProportional Hazards ModelsProstatic Neoplasms

Identifiers

PMID21720747
OpenAlexW2081325215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.